China Shineway Pharmaceutical Group
Market Cap
HK$4.3b
Last Updated
2021/05/12 10:15 UTC
Data Sources
Company Financials +
Executive Summary
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet, good value and pays a dividend.
Share Price & News
How has China Shineway Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2877 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 2877's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
4.1%
2877
-3.4%
HK Pharmaceuticals
-1.1%
HK Market
1 Year Return
7.1%
2877
15.4%
HK Pharmaceuticals
24.0%
HK Market
Return vs Industry: 2877 underperformed the Hong Kong Pharmaceuticals industry which returned 16.4% over the past year.
Return vs Market: 2877 underperformed the Hong Kong Market which returned 24.1% over the past year.
Shareholder returns
| 2877 | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.1% | -3.4% | -1.1% |
| 30 Day | 9.3% | -0.4% | -0.4% |
| 90 Day | 4.8% | -6.3% | -6.8% |
| 1 Year | 14.9%7.1% | 17.1%15.4% | 28.8%24.0% |
| 3 Year | -61.0%-66.5% | -20.4%-24.7% | 1.7%-9.1% |
| 5 Year | -4.3%-25.1% | 93.4%75.6% | 59.5%32.5% |
Long-Term Price Volatility Vs. Market
How volatile is China Shineway Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Type Of Shareholders Own The Most Number of China Shineway Pharmaceutical Group Limited (HKG:2877) Shares?1 month ago | Simply Wall St
China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet2 months ago | Simply Wall St
China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.Valuation
Is China Shineway Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2877 (HK$5.89) is trading below our estimate of fair value (HK$25.34)
Significantly Below Fair Value: 2877 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2877 is poor value based on its PE Ratio (12.5x) compared to the Hong Kong Pharmaceuticals industry average (12.3x).
PE vs Market: 2877 is poor value based on its PE Ratio (12.5x) compared to the Hong Kong market (11.6x).
Price to Earnings Growth Ratio
PEG Ratio: 2877 is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: 2877 is good value based on its PB Ratio (0.6x) compared to the HK Pharmaceuticals industry average (1.3x).
Future Growth
How is China Shineway Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
22.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2877's forecast earnings growth (22% per year) is above the savings rate (1.5%).
Earnings vs Market: 2877's earnings (22% per year) are forecast to grow faster than the Hong Kong market (17% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2877's revenue (9.8% per year) is forecast to grow slower than the Hong Kong market (12.4% per year).
High Growth Revenue: 2877's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2877's Return on Equity is forecast to be low in 3 years time (10.2%).
Past Performance
How has China Shineway Pharmaceutical Group performed over the past 5 years?
-7.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2877 has a large one-off loss of CN¥234.1M impacting its December 31 2020 financial results.
Growing Profit Margin: 2877's current net profit margins (11.1%) are lower than last year (18.6%).
Past Earnings Growth Analysis
Earnings Trend: 2877's earnings have declined by 7.2% per year over the past 5 years.
Accelerating Growth: 2877's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2877 had negative earnings growth (-41.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.9%).
Return on Equity
High ROE: 2877's Return on Equity (5.1%) is considered low.
Financial Health
How is China Shineway Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 2877's short term assets (CN¥5.5B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 2877's short term assets (CN¥5.5B) exceed its long term liabilities (CN¥224.6M).
Debt to Equity History and Analysis
Debt Level: 2877's debt to equity ratio (6.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2877's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 2877's debt is well covered by operating cash flow (172.9%).
Interest Coverage: 2877 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is China Shineway Pharmaceutical Group current dividend yield, its reliability and sustainability?
6.56%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 2877's dividend (6.56%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.96%).
High Dividend: 2877's dividend (6.56%) is in the top 25% of dividend payers in the Hong Kong market (6%)
Stability and Growth of Payments
Stable Dividend: 2877's dividend payments have been volatile in the past 10 years.
Growing Dividend: 2877's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (82.1%), 2877's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 2877's dividends in 3 years are forecast to be well covered by earnings (32.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.4yrs
Average board tenure
CEO
China Shineway Pharmaceutical Group has no CEO, or we have no data on them.
Board Members
Experienced Board: 2877's board of directors are considered experienced (6.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
China Shineway Pharmaceutical Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: China Shineway Pharmaceutical Group Limited
- Ticker: 2877
- Exchange: SEHK
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$4.331b
- Shares outstanding: 754.60m
- Website: https://www.shineway.com
Number of Employees
Location
- China Shineway Pharmaceutical Group Limited
- No. 168 Shiluan Street
- Luancheng
- Shijiazhuang
- Hebei Province
- 51430
- China
Listings
Biography
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong K...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/12 10:15 |
| End of Day Share Price | 2021/05/12 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.